In combination with insulin and metformin: moderate
Insufficient
Clinical Added Value
no clinical added value
As dual therapy in combination with insulin :
Not applicable.
As triple therapy in combination with insulin and metformin :
In the absence of direct comparative data versus an active comparator, the Transparency Committee considers that GALVUS/JALRA does not provide any improvement in actual benefit (level V, non-existent) in the treatment of patients with type 2 diabetes in combination with insulin and metformin, in patients not achieving or maintaining the glycaemic targets on a combination of insulin + metformin.
Listen
